Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.

Adenosine Diphosphate Ribose / therapeutic use Antineoplastic Agents Australia Carcinoma, Ovarian Epithelial / drug therapy Female Humans Ovarian Neoplasms / pathology Platinum Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerases Retrospective Studies
BRCA1 Protein BRCA2 Protein Medical Oncology Ovarian Cancer

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
04 07 2022
Historique:
pubmed: 25 3 2022
medline: 7 7 2022
entrez: 24 3 2022
Statut: epublish

Résumé

The primary objective of this study was to describe treatment patterns after poly-ADP ribose polymerase (PARP) inhibitor in patients with epithelial ovarian cancer. Secondary objectives were to evaluate duration of response, time to first subsequent therapy, progression-free survival and overall survival. This was a retrospective analysis of patients with epithelial ovarian cancer treated with PARP inhibitor therapy at six Australian gynecological oncology centers. Eligible patients were identified via clinics, trial databases and pharmacy dispensing logs between January 2005 and September 2019. Information regarding clinico-pathological characteristics and treatment outcomes were collated from medical records. A total of 85 patients with epithelial ovarian cancer were identified. Of these, 61% had germline Platinum doublet chemotherapy resulted in non-significant improved progression-free survival compared with other regimens, suggesting potential independent mechanisms of resistance between PARP inhibitor and platinum compounds.

Identifiants

DOI: 10.1136/ijgc-2021-003009 PMID: 35321889
pubmed: 35321889
pii: ijgc-2021-003009
doi: 10.1136/ijgc-2021-003009
doi:

Substances chimiques

Antineoplastic Agents 0
Poly(ADP-ribose) Polymerase Inhibitors 0
Adenosine Diphosphate Ribose 20762-30-5
Platinum 49DFR088MY
Poly(ADP-ribose) Polymerases EC 2.4.2.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

906-912

Informations de copyright

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Tharani Sivakumaran (T)

Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
ORCID: 0000-0001-9738-1580

Michael Krasovitsky (M)

Department of Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.
University of New South Wales Prince of Wales Clinical School, Randwick, New South Wales, Australia.

Alison Freimund (A)

Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.

Yeh Chen Lee (YC)

Department of Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.
University of New South Wales Prince of Wales Clinical School, Randwick, New South Wales, Australia.

Kate Webber (K)

Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia.
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

Jane So (J)

Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia.

Christie Norris (C)

Department of Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.

Michael Friedlander (M)

Department of Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, New South Wales, Australia.
University of New South Wales Prince of Wales Clinical School, Randwick, New South Wales, Australia.

Linda Mileshkin (L)

Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Department of Gynaecological Oncology, Mercy Hospital for Women, Heidelberg, Victoria, Australia.

George Au-Yeung (G)

Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia George.Au-Yeung@petermac.org.
Oncology and Dysplasia, The Royal Women's Hospital, Parkville, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléoside diphosphate ose › Adénosine diphosphate ose › Adénosine diphosphate ribose › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Australie › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Carcinome épithélial de l'ovaire › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Platine › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de poly(ADP-ribose) polymérases › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Glycosyltransferase › Pentosyltransferases › ADP ribose transferases › Poly(ADP-ribose) polymerases › Treatment patterns after poly-ADP ribose...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Treatment patterns after poly-ADP ribose...